Analyst Expectations For 4D Molecular Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for 4D Molecular Therapeutics (NASDAQ:FDMT) over the past quarter, with a majority being bullish or somewhat bullish. The average 12-month price target has increased to $46.33, reflecting an 11.91% rise from the previous target. Despite facing significant revenue decline and profitability challenges, the company shows strong financial management with low debt-to-equity ratio and efficient asset management.
June 07, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed ratings for 4D Molecular Therapeutics, with a majority being bullish or somewhat bullish. The average 12-month price target has increased to $46.33, reflecting an 11.91% rise from the previous target. Despite facing significant revenue decline and profitability challenges, the company shows strong financial management with low debt-to-equity ratio and efficient asset management.
The majority of analysts are bullish or somewhat bullish on FDMT, and the average price target has increased, indicating positive sentiment. However, the company faces significant revenue decline and profitability challenges, which may temper the positive outlook. Strong financial management and low debt-to-equity ratio are positive factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100